CVR number 63644919
Industry 46.4610 Wholesale of pharmaceutical goods

AMBU A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...
Bankruptcy Risk 
2016
2016/9
2017
2017/9
2018
2018/9
2019
2019/9
2020
2020/9
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.5% 0.9% 0.5% 0.5% 0.5%  
Credit score (0-100)  99 90 99 98 99  
Credit rating  AA A AA AA AA  
Credit limit (mDKK)  99.7 113.8 198.5 235.5 227.9  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2016
2016/9
2017
2017/9
2018
2018/9
2019
2019/9
2020
2020/9
Net sales  1,643 1,545 1,714 2,004 2,355  
Gross profit  627 1,545 778 985 725  
EBITDA  362 384 428 377 73.0  
EBIT  362 384 428 377 73.0  
Pre-tax profit (PTP)  338.0 456.0 422.0 498.0 91.0  
Net earnings  262.0 384.0 313.0 400.0 85.0  
Pre-tax profit without non-rec. items  338 456 422 498 91.0  
 
See the entire income statement

Balance sheet (mDKK) 
2016
2016/9
2017
2017/9
2018
2018/9
2019
2019/9
2020
2020/9
Tangible assets total  31.0 108 133 148 166  
Shareholders equity total  716 1,105 1,670 1,998 2,096  
Interest-bearing liabilities  1,100 159 128 195 398  
Balance sheet total (assets)  2,024 2,234 4,326 4,760 5,065  
Net Debt  1,080 158 116 108 330  
 
See the entire balance sheet

Volume 
2016
2016/9
2017
2017/9
2018
2018/9
2019
2019/9
2020
2020/9
Net sales  1,643 1,545 1,714 2,004 2,355  
Net sales growth  0.0% -6.0% 10.9% 16.9% 17.5%  
Gross profit  627 1,545 778 985 725  
Gross profit growth  0.0% 146.4% -49.6% 26.6% -26.4%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,024 2,234 4,326 4,760 5,065  
Balance sheet change%  0.0% 10.4% 93.6% 10.0% 6.4%  
Added value  362.0 384.0 428.0 377.0 73.0  
Added value %  22.0% 24.9% 25.0% 18.8% 3.1%  
Investments  383 209 740 132 248  
Net sales trend  0.0 -1.0 1.0 2.0 3.0  
EBIT trend  1.0 2.0 3.0 4.0 5.0  

Profitability 
2016
2016/9
2017
2017/9
2018
2018/9
2019
2019/9
2020
2020/9
EBITDA %  22.0% 24.9% 25.0% 18.8% 3.1%  
EBIT %  22.0% 24.9% 25.0% 18.8% 3.1%  
EBIT to gross profit (%)  57.7% 24.9% 55.0% 38.3% 10.1%  
Net Earnings %  15.9% 24.9% 18.3% 20.0% 3.6%  
Profit before depreciation and extraordinary items %  15.9% 24.9% 18.3% 20.0% 3.6%  
Pre tax profit less extraordinaries %  20.6% 29.5% 24.6% 24.9% 3.9%  
ROA %  18.6% 24.4% 16.1% 11.8% 4.0%  
ROI %  20.7% 32.8% 19.0% 12.7% 4.5%  
ROE %  36.6% 42.2% 22.6% 21.8% 4.2%  

Solidity 
2016
2016/9
2017
2017/9
2018
2018/9
2019
2019/9
2020
2020/9
Equity ratio %  35.4% 49.5% 38.6% 42.0% 41.4%  
Relative indebtedness %  79.6% 73.1% 155.0% 137.8% 126.1%  
Relative net indebtedness %  78.4% 73.0% 154.3% 133.5% 123.2%  
Net int. bear. debt to EBITDA, %  298.3% 41.1% 27.1% 28.6% 452.1%  
Gearing %  153.6% 14.4% 7.7% 9.8% 19.0%  
Net interest  0 0 0 0 0  
Financing costs %  7.1% 10.2% 74.6% 24.1% 35.1%  

Liquidity 
2016
2016/9
2017
2017/9
2018
2018/9
2019
2019/9
2020
2020/9
Quick Ratio  1.6 0.5 2.6 1.2 1.0  
Current Ratio  1.8 0.6 2.9 1.4 1.1  
Cash and cash equivalent  20.0 1.0 12.0 87.0 68.0  

Capital use efficiency 
2016
2016/9
2017
2017/9
2018
2018/9
2019
2019/9
2020
2020/9
Trade debtors turnover (days)  16.2 18.4 18.1 20.2 15.3  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  38.7% 40.8% 41.2% 50.6% 45.3%  
Net working capital  290.0 -379.0 465.0 264.0 97.0  
Net working capital %  17.7% -24.5% 27.1% 13.2% 4.1%  

Employee efficiency 
2016
2016/9
2017
2017/9
2018
2018/9
2019
2019/9
2020
2020/9
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0